Vaxart BARDA-Funded Project NextGen Award to $453 M for Phase 2b Study of COVID Oral Pill Vaccine

 — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —

— Vaxart anticipates initiating enrollment as early as summer 2024 —

https://www.globenewswire.com/news-release/2024/06/13/2898648/25416/en/Vaxart-Receives-BARDA-Funded-Project-NextGen-Award-Valued-Up-to-453-Million-to-Conduct-a-Phase-2b-Study-Evaluating-Its-COVID-19-Oral-Pill-Vaccine-Candidate.html